Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Buried Barrett's metaplasia eradicated after radiofrequency ablation

This month's issue of Endoscopy examines the prevalence of buried Barrett's metaplasia before and after radiofrequency ablation.

News image

Radiofrequency ablation to treat Barrett's esophagus is increasingly accepted.

Description of the etiology, natural history, and prevalence of buried Barrett's metaplasia following radiofrequency ablation is limited, although buried Barrett's metaplasia continues to pose a clinical dilemma.

Dr Yuan and colleagues assessed the prevalence, characteristics, and eradication rate of Barrett's metaplasia in patients with both dysplastic and nondysplastic Barrett's esophagus, treated with radiofrequency ablation and followed over time.

The presence of Barrett's esophagus, dysplasia, and buried Barrett's metaplasia, before and after radiofrequency ablation, was assessed by 2 gastrointestinal pathologists in a retrospective chart review of patients who had undergone radiofrequency ablation, and had completed appropriate follow-up.

The researchers identified 112 patients with completed treatment, and no further planned radiofrequency ablation.

Buried Barrett's metplasia was found in 71% during the radiofrequency ablation treatment
Endoscopy

In 108, no residual Barrett's esophagus was seen after radiofrequency ablation, and 4 patients with persistent Barrett's tissue underwent surgery.

Regarding Barrett's metaplasia, 15% of patients had evidence of buried Barrett's metaplasia during evaluation.

The team found buried Barrett's metplasia in 71% of patients during the radiofrequency ablation treatment.

The research team found that 8 patients had previously undergone non-radiofrequency ablation therapy and radiofrequency ablation for Barrett's esophagus, and 4 having no previous intervention.

In 29%, Barrett's metaplasia was seen only after radiofrequency ablation monotherapy.

The researchers observed that all 17 showed no evidence of buried Barrett's metaplasia at final evaluation, and were classified in the complete remission group.

Dr Yuan's team concluded, "Both Barrett's esophagus and buried Barrett's metaplasia were completely eradicated in all patients with long-term follow-up after radiofrequency ablation."

"Almost half of the patients with buried Barrett's metaplasia had a prior history of non-radiofrequency ablation therapy for Barrett's esophagus compared with 26% the non-Barrett's metaplasia cohort."

"All patients with previously identified Barrett's esophagus, and buried Barrett's metaplasia were completely cleared of disease at final follow-up."

Endoscopy 2012: 44(11): 993-997
23 November 2012

Go to top of page Email this page Email this page to a colleague

 28 March 2015

Advanced search
 27 March 2015 
Screening for fecal incontinence
 27 March 2015 
Deep remission in Crohn's disease
 27 March 2015 
Sexual functioning in IBD
 26 March 2015 
Antimicrobial therapy in cirrhosis with spontaneous bacterial peritonitis
 26 March 2015 
Metformin as a chemopreventive agent for Barrett's
 26 March 2015 
Survival of untreated hepatocellular carcinoma
 25 March 2015 
Genetics and Crohn's disease
 25 March 2015 
Mortality in Barrett’s–related T1 esophageal adenocarcinoma
 25 March 2015 
Cytomegalovirus and IBD
 24 March 2015 
Prevention of colorectal cancer after screening
 24 March 2015 
Functional GI disorders and body mass index
 24 March 2015 
Quality of life in children with fecal incontinence
 23 March 2015 
Fibrosis in NAFLD vs NASH
 23 March 2015 
The unmasking of Whipple's disease
 23 March 2015 
Predicting the quality of colon cancer care
 20 March 2015 
Interventions for eosinophilic esophagitis
 20 March 2015 
Colorectal cancer risk and genetic variants
 20 March 2015 
Screening for Barrett's esophagus
 19 March 2015 
Hypnotherapy for IBS
 19 March 2015 
Poor mental and physical health in HCV
 19 March 2015 
Dedicated care for diverticular disease
 18 March 2015 
Practice guidelines for colorectal polyps
 18 March 2015 
Out-of-hours endoscopy for upper GI bleeding
 18 March 2015 
H. pylori eradication and lipids
 17 March 2015 
H. pylori test-and-treat program and gastric cancer
 17 March 2015 
Adalimumab in Crohn’s disease
 17 March 2015 

Low-dose PPIs and GI bleeding in patients receiving aspirin

 16 March 2015 
Microscopic colitis
 16 March 2015 
Cholestasis of pregnancy with HCV
 16 March 2015 
Hybrid therapy for H. pylori
 13 March 2015 
Medicare patients and payments to gastroenterologists
 13 March 2015 
Appendectomy in ulcerative colitis
 13 March 2015 

Racial disparities in gluten-sensitive problems

 12 March 2015 
Predicting IBD in IBS patients
 12 March 2015 
Patient knowledge of IBS
 12 March 2015 
Nonceliac gluten sensitivity
 11 March 2015 

Prediction of malignant bile duct obstruction

 11 March 2015 
NAFLD–related hepatocellular carcinoma
 11 March 2015 
Assessment of eosinophilic esophagitis
 10 March 2015 
Risk for gastroesophageal reflux symptoms
 10 March 2015 
Poor disease course in pediatric ulcerative colitis
 10 March 2015 
Outcomes in Crohn's therapy
 09 March 2015 
Fibre usage in ulcerative colitis in remission
 09 March 2015 
Gastric Cancer detection during GI endosocopy
 09 March 2015 
Risk of C. difficile upon hospital admission
 06 March 2015 
Second anti-TNF in IBD
 06 March 2015 
Efficacy of Hep E vaccine
 06 March 2015 
Steroid therapy for eosinophilic esophagitis
 05 March 2015 
EPHXI polymorphism and esophageal cancer risk
 05 March 2015 
Infliximab and immunosuppressant therapy in ulcerative colitis
 05 March 2015 
Neuroendocrine carcinoma of the colon and rectum
 04 March 2015 
Multidisciplinary management of rectal cancer
 04 March 2015 
Management of IBD
 04 March 2015 
Progression of Barrett's
 03 March 2015 
EPHX1 polymorphism and esophageal cancer risk
 03 March 2015 
GI bleeding in chronic kidney disease patients on aspirin
 03 March 2015 
Risk of anastomotic leak after colectomy
 02 March 2015 
Genes and early diagnosis of IBD
 02 March 2015 
Assessment of GERD
 02 March 2015 
Liver disease in patients awaiting liver transplant

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us